Research programme: transcription factor therapeutics - Odyssey Therapeutics/Terray Therapeutics
Latest Information Update: 12 Nov 2024
Price :
$50 *
At a glance
- Originator Odyssey Therapeutics; Terray Therapeutics
- Class Anti-inflammatories; Small molecules
- Mechanism of Action Transcription factor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Inflammation
Most Recent Events
- 28 Oct 2024 Odyssey Therapeutics and Terray Therapeutics agree to co-develop transcription factor therapeutics in the USA for Inflammation
- 28 Oct 2024 Early research in Inflammation in USA (unspecified route)